Search results
6 paź 2017 · The aim of this guideline was to produce recommendations for the management of adult lupus patients in the UK that cover the diagnosis, assessment and monitoring of lupus and the treatment of mild, moderate and severe active lupus disease, but which do not imply a legal obligation.
2 sty 2024 · The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
For active lupus nephritis, GC, mycophenolate or low- dose intravenous CYC are recommended as anchor drugs, and add- on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered.
The 2008 EULAR recommendations for the management of systemic lupus erythematosus (SLE) have been updated in 2019 [1], using a classical methodology (systematic literature review, followed by modified Delphi method to form questions, elicit expert opinions and reach consensus).
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
